PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33034105-7	2021	In addition, this study highlights the inequivalence of rivaroxaban binding to mammalian serum albumin.	Rivaroxaban	56-67	albumin	Homo sapiens	89-102	
32279215-0	2020	Albumin and bleed risk in rivaroxaban treated patients.	Rivaroxaban	26-37	albumin	Homo sapiens	0-7	
32279215-2	2020	Rivaroxaban is 92-95% protein bound, but the clinical effects of rivaroxaban in patients with low albumin are largely unknown.	Rivaroxaban	65-76	albumin	Homo sapiens	98-105	
32279215-3	2020	The purpose of this study was to evaluate the relationship between albumin and bleeding in rivaroxaban treated patients.	Rivaroxaban	91-102	albumin	Homo sapiens	67-74	
32279215-8	2020	The mean +- standard deviation albumin level nearest to the time of rivaroxaban initiation was significantly lower in patients who experienced a bleeding event (3.0 +- 0.75 g/dL vs 3.66 +- 0.54 g/dL, p < 0.0001).	Rivaroxaban	68-79	albumin	Homo sapiens	31-38	
32279215-11	2020	Albumin levels were significantly associated with bleed risk in patients receiving rivaroxaban.	Rivaroxaban	83-94	albumin	Homo sapiens	0-7	
32279215-12	2020	Albumin levels should be considered when evaluating candidates for rivaroxaban therapy.	Rivaroxaban	67-78	albumin	Homo sapiens	0-7